Merus Labs International Inc. (NASDAQ:MSLI)‘s stock had its “hold” rating reissued by research analysts at Paradigm Capital in a research note issued to investors on Wednesday. They currently have a $1.60 price target on the stock, down from their previous price target of $1.75. Paradigm Capital’s price objective indicates a potential upside of 58.42% from the company’s previous close.

Other research analysts have also issued reports about the stock. Citigroup Inc. reissued a “buy” rating and set a $14.00 price objective on shares of Merus Labs International in a report on Monday, June 13th. Guggenheim reissued a “buy” rating on shares of Merus Labs International in a report on Monday, June 13th. Canaccord Genuity reissued a “buy” rating on shares of Merus Labs International in a report on Friday, August 12th. Zacks Investment Research raised shares of Merus Labs International from a “strong sell” rating to a “hold” rating in a report on Thursday, July 14th. Finally, Wedbush reissued an “outperform” rating on shares of Merus Labs International in a report on Monday, June 13th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. Merus Labs International presently has a consensus rating of “Hold” and a consensus target price of $4.41.

Merus Labs International (NASDAQ:MSLI) opened at 1.01 on Wednesday. The stock’s 50 day moving average is $1.01 and its 200-day moving average is $1.27. The firm’s market capitalization is $118.17 million. Merus Labs International has a 52 week low of $0.92 and a 52 week high of $1.90.

Merus Labs International (NASDAQ:MSLI) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by $0.03. Merus Labs International had a negative return on equity of 3.41% and a negative net margin of 12.89%. On average, equities research analysts expect that Merus Labs International will post ($0.07) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. TD Asset Management Inc. boosted its position in Merus Labs International by 8.1% in the second quarter. TD Asset Management Inc. now owns 182,092 shares of the company’s stock valued at $231,000 after buying an additional 13,681 shares during the period. Bank of Montreal Can purchased a new position in Merus Labs International during the second quarter valued at approximately $103,000. Vertex One Asset Management Inc. boosted its position in Merus Labs International by 57.4% in the second quarter. Vertex One Asset Management Inc. now owns 314,700 shares of the company’s stock valued at $400,000 after buying an additional 114,700 shares during the period. Royal Bank of Canada boosted its position in Merus Labs International by 541.4% in the first quarter. Royal Bank of Canada now owns 136,654 shares of the company’s stock valued at $200,000 after buying an additional 115,349 shares during the period. Finally, Guardian Capital LP boosted its position in Merus Labs International by 21.1% in the second quarter. Guardian Capital LP now owns 1,208,400 shares of the company’s stock valued at $1,533,000 after buying an additional 210,500 shares during the period. Hedge funds and other institutional investors own 25.73% of the company’s stock.

About Merus Labs International

Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.

5 Day Chart for NASDAQ:MSLI

Receive News & Stock Ratings for Merus Labs International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc. and related stocks with our FREE daily email newsletter.